Safety Topics
Side-effect and safety topics — each article grounded in published trial data.
Side effects, safety signals, and longer-term concerns for retatrutide and the wider GLP-1 class. Every article here is grounded in published trial data — not anecdote.
Related topic hubs
- Guides — How to manage side effects day-to-day
- Drugs — Safety profile by drug
- Retatrutide — Retatrutide-specific safety data
Class-wide safety signals at a glance
Frequency below reflects published trials for each drug class at the high-dose, long-duration endpoints. Severity is the typical clinical grade when the signal occurs.
| Signal | GLP-1 | Dual agonist | Triple agonist | Severity | Deep dive |
|---|---|---|---|---|---|
| Nausea / vomiting | ~40–45% | ~30–35% | ~35–40% | Mostly mild–moderate | Side effects |
| Constipation / diarrhea | ~20% | ~20% | ~20% | Mild–moderate | — |
| Muscle / lean-mass loss | ~25–40% of total loss | ~25–40% | ~25–40% | Clinically relevant at high weight loss | Muscle loss |
| Hair loss (telogen effluvium) | ~3–5% | ~5% | Unreported; higher weight loss → higher risk | Usually reversible | Hair loss |
| Dysesthesia (skin-prickling) | Rare | Rare | Reported at 12 mg (Phase 2) | Mild | Side effects |
| Mental-health signal | No elevated rate in trials | No elevated rate | Too early | Monitor in at-risk users | Mental health |
Populations with extra caution
- Pregnancy & fertility — full article. GLP-1 drugs are not recommended during pregnancy; contraception is advised around contraceptive absorption questions.
- Women — sex-specific considerations, including PCOS, bone density, and cycle effects.
- Alcohol — interaction profile.
- Food noise — appetite and reward. Not a side effect, but an important mechanism readers often ask about.
- Grey-market use — contamination and counterfeit risks.
Numbers above are class-level approximations drawn from the TRIUMPH, SURMOUNT, STEP, REDEFINE, and SURPASS programs. For drug-specific incidence and source citations, see the individual articles linked in each row.
All safety articles
9 articles
Does Retatrutide Cause Muscle Loss?
The first DXA body composition data for retatrutide, the glucagon muscle-sparing hypothesis, and evidence-based strategies to preserve lean mass.
Updated February 2026
GLP-1 Drugs and Mental Health: What the Evidence Actually Shows
The FDA cleared GLP-1 drugs of psychiatric risk after reviewing 91 trials. The surprising finding: these drugs may actually improve depression.
Updated March 2026
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.
Updated February 2026
How to Reconstitute Retatrutide (and Why You Shouldn't)
Pharmaceutical retatrutide does not require reconstitution — it comes pre-filled. Grey market powder reconstitution is dangerous.
Updated February 2026
Retatrutide and Alcohol: What We Know
No direct studies exist on retatrutide and alcohol, but GLP-1 receptor agonist research points to reduced intake and liver effects.
Updated February 2026
Retatrutide and Food Noise: How Triple Agonism Quiets Cravings
How retatrutide's three receptors each contribute a distinct mechanism to reducing food noise, and what the Phase 2 data shows.
Updated March 2026
Retatrutide and Pregnancy: What Triple Agonism Means for Fertility and Safety
Three receptors, three pregnancy concerns. What GLP-1, GIP, and glucagon receptor research means for retatrutide and reproductive safety.
Updated March 2026
Retatrutide Side Effects & Safety
Clinical trial safety data, the new dysesthesia signal, and how side effects compare to existing GLP-1 drugs.
Updated February 2026
Weight Loss Drugs and Hair Loss: What Retatrutide's 24% Weight Loss Means
More weight loss means more hair shedding. Retatrutide's 24% weight loss likely puts it at the top — here's the clinical data and what to do about it.
Updated March 2026